Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis

Background Anaerobic bacteria are increasingly regarded as important in cystic fibrosis (CF) pulmonary infection. The aim of this study was to determine the effect of antibiotic treatment on aerobic and anaerobic microbial community diversity and abundance during exacerbations in patients with CF. Methods Sputum was collected at the start and completion of antibiotic treatment of exacerbations and when clinically stable. Bacteria were quantified and identified following culture, and community composition was also examined using culture-independent methods. Results Pseudomonas aeruginosa or Burkholderia cepacia complex were detected by culture in 24/26 samples at the start of treatment, 22/26 samples at completion of treatment and 11/13 stable samples. Anaerobic bacteria were detected in all start of treatment and stable samples and in 23/26 completion of treatment samples. Molecular analysis showed greater bacterial diversity within sputum samples than was detected by culture; there was reasonably good agreement between the methods for the presence or absence of aerobic bacteria such as P aeruginosa (κ=0.74) and B cepacia complex (κ=0.92), but agreement was poorer for anaerobes. Both methods showed that the composition of the bacterial community varied between patients but remained relatively stable in most individuals despite treatment. Bacterial abundance decreased transiently following treatment, with this effect more evident for aerobes (median decrease in total viable count 2.3×107 cfu/g, p=0.005) than for anaerobes (median decrease in total viable count 3×106 cfu/g, p=0.046). Conclusion Antibiotic treatment targeted against aerobes had a minimal effect on abundance of anaerobes and community composition, with both culture and molecular detection methods required for comprehensive characterisation of the microbial community in the CF lung. Further studies are required to determine the clinical significance of and optimal treatment for these newly identified bacteria.

[1]  M. Tunney,et al.  Detection Of Anaerobic Bacteria In Stable Non-Cystic Fibrosis Bronchiectasis Patients , 2010, ATS 2010.

[2]  Eoin L. Brodie,et al.  A persistent and diverse airway microbiota present during chronic obstructive pulmonary disease exacerbations. , 2010, Omics : a journal of integrative biology.

[3]  G. Rogers,et al.  Determining Cystic Fibrosis-Affected Lung Microbiology: Comparison of Spontaneous and Serially Induced Sputum Samples by Use of Terminal Restriction Fragment Length Polymorphism Profiling , 2009, Journal of Clinical Microbiology.

[4]  M. Wolfgang,et al.  Detection of anaerobic bacteria in bronchoalveolar lavage fluid from paediatric CF patients , 2009 .

[5]  J. Sarles,et al.  Microbial diversity in the sputum of a cystic fibrosis patient studied with 16S rDNA pyrosequencing , 2009, European Journal of Clinical Microbiology & Infectious Diseases.

[6]  G. Döring,et al.  Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  M. Surette,et al.  A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients , 2008, Proceedings of the National Academy of Sciences.

[8]  J. Sarles,et al.  Molecular Detection of Multiple Emerging Pathogens in Sputa from Cystic Fibrosis Patients , 2008, PloS one.

[9]  M. Wolfgang,et al.  Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. , 2008, American journal of respiratory and critical care medicine.

[10]  N. Pace,et al.  Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis , 2007, Proceedings of the National Academy of Sciences.

[11]  M. Stanton,et al.  Cystic fibrosis mortality and survival in the UK: 1947–2003 , 2007, European Respiratory Journal.

[12]  G. Rogers,et al.  Use of 16S rRNA Gene Profiling by Terminal Restriction Fragment Length Polymorphism Analysis To Compare Bacterial Communities in Sputum and Mouthwash Samples from Patients with Cystic Fibrosis , 2006, Journal of Clinical Microbiology.

[13]  L. Saiman,et al.  The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. , 2005, Chest.

[14]  G. Rogers,et al.  Bacterial activity in cystic fibrosis lung infections , 2005, Respiratory research.

[15]  G. Rogers,et al.  Characterization of Bacterial Community Diversity in Cystic Fibrosis Lung Infections by Use of 16S Ribosomal DNA Terminal Restriction Fragment Length Polymorphism Profiling , 2004, Journal of Clinical Microbiology.

[16]  C. Hart,et al.  Bacterial Diversity in Cases of Lung Infection in Cystic Fibrosis Patients: 16S Ribosomal DNA (rDNA) Length Heterogeneity PCR and 16S rDNA Terminal Restriction Fragment Length Polymorphism Profiling , 2003, Journal of Clinical Microbiology.

[17]  J. Emerson,et al.  Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. , 2003, American journal of respiratory and critical care medicine.

[18]  Richard C Boucher,et al.  Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. , 2002, The Journal of clinical investigation.

[19]  F. Ratjen.  Changes in strategies for optimal antibacterial therapy in cystic fibrosis. , 2001, International journal of antimicrobial agents.

[20]  P. Vandamme,et al.  Development of rRNA-Based PCR Assays for Identification of Burkholderia cepacia Complex Isolates Recovered from Cystic Fibrosis Patients , 1999, Journal of Clinical Microbiology.

[21]  G. Redding,et al.  Comparison of a β-lactam alone versus β-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis , 1999 .

[22]  M. Denton,et al.  Acute bronchopulmonary infection due toStreptococcus milleri in a child with cystic fibrosis , 1999, Archives of disease in childhood.

[23]  G. Grollier,et al.  Incidence of anaerobes in ventilator-associated pneumonia with use of a protected specimen brush. , 1996, American journal of respiratory and critical care medicine.

[24]  P. Potgieter,et al.  The etiology and antimicrobial susceptibility patterns of microorganisms in acute community-acquired lung abscess. , 1995, Chest.

[25]  Aldridge Ke.  The occurrence, virulence, and antimicrobial resistance of anaerobes in polymicrobial infections , 1995 .

[26]  K. Schleifer,et al.  Phylogenetic identification and in situ detection of individual microbial cells without cultivation. , 1995, Microbiological reviews.

[27]  H. Fuchs,et al.  Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. , 1994, The New England journal of medicine.

[28]  I. Brook,et al.  Aerobic and anaerobic microbiology of empyema. A retrospective review in two military hospitals. , 1993, Chest.

[29]  W. Warwick,et al.  Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. , 1990, The American review of respiratory disease.

[30]  R. Spencer,et al.  The incidence of anaerobes in the sputum of patients with cystic fibrosis. , 1990, Journal of medical microbiology.

[31]  R. Stern,et al.  Cultures of thoracotomy specimens confirm usefulness of sputum cultures in cystic fibrosis. , 1984, The Journal of pediatrics.

[32]  Alexander Rokitansky,et al.  Thorax , 2009, Pediatric Surgery Digest.

[33]  G. Rogers,et al.  Use of 16 S rRNA Gene Profiling by Terminal Restriction Fragment Length Polymorphism Analysis To Compare Bacterial Communities in Sputum and Mouthwash Samples from Patients with Cystic Fibrosis † , 2006 .

[34]  Neil Hunter,et al.  Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set. , 2002, Microbiology.

[35]  G. Redding,et al.  Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. , 1999, The Journal of pediatrics.

[36]  K. Aldridge.  The occurrence, virulence, and antimicrobial resistance of anaerobes in polymicrobial infections. , 1995, American journal of surgery.

[37]  B. Langer.  "Don't look back--something might be gaining on you". , 1995, American journal of surgery.

[38]  I. Brook,et al.  Transtracheal aspiration in pulmonary infection in children with cystic fibrosis. , 1983, European journal of respiratory diseases.